Additional targets include beta-catenin signaling, which is known to protect LSCs from TKIs [67], as well as TNF and VEGFA, which may be involved in other types of treatment resistance in CML [68, 69]. This evidence concerns the gene TNF and chronic myelogenous leukemia, BCR-ABL1 positive.